CY1108843T1 - 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων - Google Patents

3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων

Info

Publication number
CY1108843T1
CY1108843T1 CY20091100221T CY091100221T CY1108843T1 CY 1108843 T1 CY1108843 T1 CY 1108843T1 CY 20091100221 T CY20091100221 T CY 20091100221T CY 091100221 T CY091100221 T CY 091100221T CY 1108843 T1 CY1108843 T1 CY 1108843T1
Authority
CY
Cyprus
Prior art keywords
schizophrenia
cis
treatment
dimrodetretravenasine
psychologies
Prior art date
Application number
CY20091100221T
Other languages
English (en)
Inventor
Andrew John Duffield
Jean Elisabeth Yarrow
Original Assignee
Biovail Laboratories International (Barbados) Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by Biovail Laboratories International (Barbados) Srl filed Critical Biovail Laboratories International (Barbados) Srl
Publication of CY1108843T1 publication Critical patent/CY1108843T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση παρέχει την χρήση της 3,11b-cis-διϋδροτετραβεναζίνης ή ενός φαρμακευτικώς αποδεκτού άλατος αυτής για την κατασκευή ενός φαρμάκου για την προφύλαξη ή την θεραπεία της σχιζοφρένιας και άλλων ψυχώσεων.
CY20091100221T 2005-08-06 2009-02-26 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων CY1108843T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds
EP06765238A EP1855677B1 (en) 2005-08-06 2006-08-04 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Publications (1)

Publication Number Publication Date
CY1108843T1 true CY1108843T1 (el) 2014-07-02

Family

ID=37400949

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100221T CY1108843T1 (el) 2005-08-06 2009-02-26 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων

Country Status (21)

Country Link
US (1) US20110257220A1 (el)
EP (2) EP1855677B1 (el)
JP (1) JP2009504622A (el)
KR (1) KR20080033500A (el)
AT (2) ATE534391T1 (el)
AU (1) AU2006277753B2 (el)
CA (1) CA2620960A1 (el)
CY (1) CY1108843T1 (el)
DE (1) DE602006004009D1 (el)
DK (1) DK1855677T3 (el)
ES (1) ES2318771T3 (el)
HK (1) HK1111083A1 (el)
HR (1) HRP20090074T3 (el)
MX (1) MX2008001549A (el)
NZ (1) NZ566011A (el)
PL (1) PL1855677T3 (el)
PT (1) PT1855677E (el)
RS (1) RS50807B (el)
RU (1) RU2407743C2 (el)
SI (1) SI1855677T1 (el)
WO (1) WO2007017654A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
KR101882044B1 (ko) 2011-04-01 2018-07-25 쓰리엠 이노베이티브 프로퍼티즈 캄파니 트라이아진계 자외선 흡수제를 포함하는 필름
US20160346270A1 (en) 2014-01-27 2016-12-01 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6718376B2 (ja) * 2014-02-07 2020-07-08 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
EP3368534B1 (en) 2015-10-30 2021-01-27 Neurocrine Biosciences, Inc. Valbenazine ditosylate and polymorphs thereof
HRP20220621T1 (hr) 2015-12-23 2022-06-24 Neurocrine Biosciences, Inc. Postupak sinteze za proizvodnju (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
JP2020500875A (ja) * 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
CA3051832A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
EP3684333A2 (en) 2017-09-21 2020-07-29 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN111836543A (zh) 2017-10-10 2020-10-27 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
WO2020037022A1 (en) 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) 1958-04-15 Quinolizine derivatives
US2843591A (en) * 1958-07-15 Method for preparing same
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP2050451B1 (en) 2011-11-23
KR20080033500A (ko) 2008-04-16
MX2008001549A (es) 2008-04-04
US20110257220A1 (en) 2011-10-20
AU2006277753A1 (en) 2007-02-15
NZ566011A (en) 2011-01-28
EP1855677B1 (en) 2008-12-03
ATE415968T1 (de) 2008-12-15
JP2009504622A (ja) 2009-02-05
EP2050451A1 (en) 2009-04-22
RS50807B (sr) 2010-08-31
RU2008108623A (ru) 2009-09-20
HRP20090074T3 (en) 2009-04-30
HK1111083A1 (en) 2008-08-01
EP1855677A1 (en) 2007-11-21
WO2007017654A1 (en) 2007-02-15
PL1855677T3 (pl) 2009-07-31
CA2620960A1 (en) 2007-02-15
SI1855677T1 (sl) 2009-04-30
AU2006277753B2 (en) 2011-11-10
PT1855677E (pt) 2009-01-13
ATE534391T1 (de) 2011-12-15
ES2318771T3 (es) 2009-05-01
DK1855677T3 (da) 2009-02-09
RU2407743C2 (ru) 2010-12-27
DE602006004009D1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
CY1115426T1 (el) 1,3-δισυποκατεστημενα παραγωγα ιμιδαζολιδιν-2-ονης ως αναστολεις toy cyp 17
MY148491A (en) FUSED BICYCLIC mTOR INHIBITORS
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CY1113766T1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1113108T1 (el) Μεσυλικο προφαρμακου λεβοντοπα, συνθεσεις αυτου, και χρησεις αυτου
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
CY1108729T1 (el) 3,11b-cis-διυδpotetpabenazinh για την θεραπευτικη αντιμετωπιση μιας πολλαπλασιαστικης νοσου ή φλεγμονωδους παθησης
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
SE0301650D0 (sv) Novel compounds
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
CY1115949T1 (el) Παραγωγα διοξα-δικυκλο[3.2.1]οκταν-2,3,4-τριολης
UA94070C2 (ru) КОНДЕНСИРОВАННЫЕ БИЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ mTOR
CY1114328T1 (el) Αμινοκινολονες ως gsk-3 αναστολεις